283 related articles for article (PubMed ID: 10951340)
1. A phase II study of paclitaxel-ifosfamide-cisplatin combination in advanced nonsmall cell lung carcinoma.
Kosmas C; Tsavaris NB; Polyzos A; Kalofonos HP; Sepsas E; Malamos NA; Vadiaka M; Dosios T; Antonopoulos MJ
Cancer; 2000 Aug; 89(4):774-82. PubMed ID: 10951340
[TBL] [Abstract][Full Text] [Related]
2. A phase I-II study of docetaxel-ifosfamide-cisplatin (DIP) combination chemotherapy regimen in advanced nonsmall cell lung cancer.
Kosmas C; Tsavaris NB; Makatsoris T; Onyenadum A; Vadiaka M; Stavroyianni N; Sepsas E; Dimitropoulos D; Rokana S; Kalofonos HP
Int J Cancer; 2002 Mar; 98(1):141-7. PubMed ID: 11857398
[TBL] [Abstract][Full Text] [Related]
3. Gemcitabine and docetaxel as second-line chemotherapy for patients with nonsmall cell lung carcinoma who fail prior paclitaxel plus platinum-based regimens.
Kosmas C; Tsavaris N; Vadiaka M; Stavroyianni N; Koutras A; Malamos N; Onyenadum A; Rokana S; Polyzos A; Kalofonos HP
Cancer; 2001 Dec; 92(11):2902-10. PubMed ID: 11753965
[TBL] [Abstract][Full Text] [Related]
4. Phase II study of paclitaxel, ifosfamide, and cisplatin as second-line treatment in relapsed small-cell lung cancer.
Kosmas C; Tsavaris NB; Malamos NA; Vadiaka M; Koufos C
J Clin Oncol; 2001 Jan; 19(1):119-26. PubMed ID: 11134204
[TBL] [Abstract][Full Text] [Related]
5. Gemcitabine and vinorelbine as second-line therapy in non-small-cell lung cancer after prior treatment with taxane+platinum-based regimens.
Kosmas C; Tsavaris N; Panopoulos C; Vadiaka M; Stavroyianni N; Kourelis T; Malamos N; Antonopoulos M; Kalofonos HP
Eur J Cancer; 2001 May; 37(8):972-8. PubMed ID: 11334721
[TBL] [Abstract][Full Text] [Related]
6. A phase II study of the docetaxel-ifosfamide-carboplatin combination in advanced non-small-cell lung cancer.
Kosmas C; Tsavaris N; Koutras A; Makatsoris T; Mylonakis N; Tzelepis G; Dimitrakopoulos A; Spyropoulos K; Polyzos A; Karabelis A; Kalofonos HP
Oncology; 2005; 69(4):333-41. PubMed ID: 16282711
[TBL] [Abstract][Full Text] [Related]
7. A phase I-II study of bi-weekly gemcitabine and irinotecan as second-line chemotherapy in non-small cell lung cancer after prior taxane + platinum-based regimens.
Kosmas C; Tsavaris N; Syrigos K; Koutras A; Tsakonas G; Makatsoris T; Mylonakis N; Karabelis A; Stathopoulos GP; Kalofonos HP
Cancer Chemother Pharmacol; 2007 Jan; 59(1):51-9. PubMed ID: 16622691
[TBL] [Abstract][Full Text] [Related]
8. A phase II study of paclitaxel plus cisplatin for advanced non-small-cell lung cancer in Japanese patients.
Sakai H; Yoneda S; Tamura T; Nishiwaki Y; Yokoyama A; Watanabe K; Saijo N
Cancer Chemother Pharmacol; 2001 Dec; 48(6):499-503. PubMed ID: 11800032
[TBL] [Abstract][Full Text] [Related]
9. Gemcitabine, ifosfamide, cisplatin (GIP) for the treatment of advanced non-small cell lung cancer: a phase II study of the italian oncology group for clinical research (GOIRC).
Boni C; Bisagni G; Savoldi L; Moretti G; Rondini E; Sassi M; Zadro A; De Pas T; Franciosi V; Pazzola A; Vignoli R; Banzi MC; Pajetta V
Int J Cancer; 2000 Sep; 87(5):724-7. PubMed ID: 10925367
[TBL] [Abstract][Full Text] [Related]
10. Phase II study of pemetrexed disodium, a multitargeted antifolate, and cisplatin as first-line therapy in patients with advanced nonsmall cell lung carcinoma: a study of the National Cancer Institute of Canada Clinical Trials Group.
Shepherd FA; Dancey J; Arnold A; Neville A; Rusthoven J; Johnson RD; Fisher B; Eisenhauer E
Cancer; 2001 Aug; 92(3):595-600. PubMed ID: 11505404
[TBL] [Abstract][Full Text] [Related]
11. A randomized phase II study of ifosfamide/mesna/cisplatin plus G-CSF or etoposide/cisplatin plus G-CSF in advanced non-small cell lung cancer: a Cancer and Leukemia Group B study.
Graziano SL; Valone FH; Herndon JE; Crawford J; Richards F; Rege VB; Clamon G; Green MR
Lung Cancer; 1996 Jun; 14(2-3):315-29. PubMed ID: 8794413
[TBL] [Abstract][Full Text] [Related]
12. Sequential therapy in advanced non-small-cell lung cancer with weekly paclitaxel followed by cisplatin-gemcitabine-vinorelbine. A phase II study.
Feliu J; Martin G; Lizón J; Chacón JI; Dorta J; de Castro J; Rodríguez A; Sánchez Heras B; Torrego JC; Espinosa E; González Barón M;
Ann Oncol; 2001 Oct; 12(10):1369-74. PubMed ID: 11762806
[TBL] [Abstract][Full Text] [Related]
13. Phase II study of docetaxel and ifosfamide combination chemotherapy in non-small-cell lung cancer patients failing previous chemotherapy with or without paclitaxel.
Chen YM; Shih JF; Lee CS; Chen MC; Lin WC; Tsai CM; Perng RP
Lung Cancer; 2003 Feb; 39(2):209-14. PubMed ID: 12581575
[TBL] [Abstract][Full Text] [Related]
14. Paclitaxel by 24- or 1-hour infusion n combination with carboplatin in advanced non-small cell lung cancer: the Fox Chase Cancer Center experience.
Langer CJ; Leighton JC; Comis RL; O'Dwyer PJ; McAleer CA; Bonjo CA; Engstrom PF; Litwin S; Johnson S; Ozols RF
Semin Oncol; 1995 Aug; 22(4 Suppl 9):18-29. PubMed ID: 7544025
[TBL] [Abstract][Full Text] [Related]
15. Phase I study of dose-escalated paclitaxel, ifosfamide, and cisplatin (PIC) combination chemotherapy in advanced solid tumours.
Kosmas C; Tsavaris NB; Polyzos A; Malamos NA; Katsikas M; Antonopoulos MJ
Br J Cancer; 2000 Jan; 82(2):300-7. PubMed ID: 10646881
[TBL] [Abstract][Full Text] [Related]
16. Paclitaxel and carboplatin in combination in the treatment of advanced non-small-cell lung cancer: a phase II toxicity, response, and survival analysis.
Langer CJ; Leighton JC; Comis RL; O'Dwyer PJ; McAleer CA; Bonjo CA; Engstrom PF; Litwin S; Ozols RF
J Clin Oncol; 1995 Aug; 13(8):1860-70. PubMed ID: 7543559
[TBL] [Abstract][Full Text] [Related]
17. Ifosfamide/carboplatin/etoposide/paclitaxel in advanced lung cancer: update and preliminary survival analysis.
Strauss GM; Lynch TJ; Elias AD; Jacobs C; Herbst R; Leong T; Lynch C; Kwiatkowski DJ; Carey RW; Grossbard ML; Skarin AT
Semin Oncol; 1997 Aug; 24(4 Suppl 12):S12-73-S12-80. PubMed ID: 9331127
[TBL] [Abstract][Full Text] [Related]
18. Paclitaxel, cisplatin, and gemcitabine combination chemotherapy within a multidisciplinary therapeutic approach in metastatic nonsmall cell lung carcinoma.
Rodriguez J; Cortes J; Calvo E; Azinovic I; Fernandez-Hildago O; Martinez-Monge R; Garzon C; de Irala J; Martinez-Aguillo M; Ramon Y Cajal T; Brugarolas A
Cancer; 2000 Dec; 89(12):2622-9. PubMed ID: 11135224
[TBL] [Abstract][Full Text] [Related]
19. Phase II study of a closely spaced ifosfamide--cisplatin schedule with the addition of G-CSF in advanced non-small-cell lung cancer and malignant melanoma.
Planting AS; de Wit R; van der Burg ME; Stoter G; Verweij J
Ann Oncol; 1996 Dec; 7(10):1080-2. PubMed ID: 9037369
[TBL] [Abstract][Full Text] [Related]
20. Phase II study of tamoxifen, ifosfamide, epirubicin and cisplatin combination chemotherapy in patients with non-small cell lung cancer failing previous chemotherapy.
Chen Y; Perng RP; Yang KY; Lin WC; Wu HW; Tsai CM; Whang-Peng J
Lung Cancer; 2000 Aug; 29(2):139-46. PubMed ID: 10963844
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]